Cardinal Health Inc. - Providence Business News

Home Tags Cardinal Health Inc.

R.I. recovers $30M from Purdue Pharma in latest opioid settlement

Government 06/16/2025

PROVIDENCE – Rhode Island has recovered nearly $30 million after all 55 attorneys general representing all eligible states and U.S. territories approved a $7.4...

ATTORNEY GENERAL PETER F. NERONHA announced on Jan. 25 that Rhode Island settled lawsuits related to the opioid crisis with multinational corporation Johnson & Johnson and pharmaceutical distributors Cardinal Health Inc., McKesson Corp. and AmerisourceBergen Corp. for a total of $114 million. / SCREENSHOT OF PRESS CONFERENCE ON WPRI-TV CBS 12

R.I. to get $114 million from opioid lawsuit settlements

Government 01/25/2022

PROVIDENCE – Attorney General Peter F. Neronha announced on Tuesday that his office reached a $9.8 million settlement with American multinational corporation Johnson &...

A FEDERAL JUDGE has decided makers and distributors of opioid painkillers must face lawsuits claiming they banded together to wrongfully push sales of the addictive pills ahead of the first federal trial on the matter expected to take place next month. / BLOOMBERG NEWS FILE PHOTO/DHIRAJ SINGH

Big pharma ordered to face cities’ opioid-conspiracy claims

Government 09/03/2019

WILMINGTON, Del. – Johnson & Johnson, Cardinal Health Inc. and other makers and distributors of opioid painkillers must face lawsuits claiming they banded together...

MCKESSON CORP., Cardinal Health Inc. and AmerisourceBergen Corp. have proposed paying $10 billion to settle claims they helped to fuel the United States opioid epidemic. / BLOOMBERG NEWS FILE PHOTO/DHIRAJ SINGH

Opioid distributors propose $10B to end state claims

Government 08/06/2019

WILMINGTON, Del. – McKesson Corp., Cardinal Health Inc. and AmerisourceBergen Corp. have proposed paying $10 billion to settle claims they helped to fuel the...

- Featured Event -

Latest News

SUBSCRIBE TO

PBN's All Access Subscription

PBN subscribers get ahead with unlimited access to PBN news, information, and insights from our editorial team, research and data, webinars and much more.